Phase I study to assess safety and tolerability of investigative medication in pediatric patients with Sanfilippo syndrome (MPS IIIA)

Phase I study to assess safety and tolerability of investigative medication in pediatric patients with Sanfilippo syndrome (MPS IIIA)

A specialty healthcare company developing treatments for rare diseases sought Raremark’s support for an early-stage pediatric trial program testing an investigational medicine in Sanfilippo syndrome. Raremark was commissioned to run a nine-month online campaign to raise the profile of the program and to find and refer up to four of the nine patients needed for the Phase I study in the United States; to a study site that initially had no patients of their own.

We found, prescreened and referred three eligible children and their parents within three weeks of study start-up.

Download the Xperiome case study Phase I study to assess safety and tolerability of investigative medication in pediatric patients with Sanfilippo syndrome (MPS IIIA).

Get in touch with us

Interested in working with us? We’d love to hear from you. Please complete the form below and we’ll be in touch


All fields required
Maximum 300 characters

US: +1 (972) 382 7227

UK: +44 (0) 20 3920 9880